Positive results from influenza human challenge study conducted by hVIVO
hVIVO PLC (AIM:HVO) World Vaccine Congress Presentation
hVIVO plc (AIM & Euronext: HVO) , (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using
hVIVO PLC (AIM:HVO) Omicron human challenge model update
hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human
hVIVO PLC (AIM:HVO) £6.8m RSV human challenge contract signed. Second contract with an APAC client in 2023
hVIVO plc (AIM & Euronext: HVO) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces
hVIVO shares: further to go in 2023? Worth circa 5p per share pre-pandemic
hVIVO saw record revenues for another year in 2022 as demand for its human challenge trials accelerated. And 2023 could see further gains.
hVIVO PLC (AIM:HVO) Trading update
EBITDA significantly ahead of expectations Orderbook growth and improved operational delivery lays strong foundations for future growth
hVIVO PLC (AIM:HVO) EUR3.2m Venn contract with global pharma client
€3.2m contract for Venn Life Sciences with global pharmaceutical client
hVIVO PLC (AIM:HVO) £5.2m RSV contract and Notice of Trading update
£5.2m RSV human challenge study contract with global biotechnology company in Asia Pacific and Notice of Trading Update
Cathal Friel, chairman and co-founder of Poolbeg Pharma. What keeps him going is ‘the fun and enjoyment of creating companies’
Cathal Friel’s latest venture, Poolbeg Pharma, a clinical-stage infectious disease firm spun out of Open Orphan, aims to tap into the almost €200 billion infectious disease market.
hVIVO PLC (AIM:HVO) Imutex Phase I data published
Phase I results for Imutex’s mosquito vaccine candidate published in leading peer-reviewed journal
hVIVO PLC (AIM:HVO) £13.6m RSV human challenge study contract with biopharma client
Study cohort sizes increase as clients recognise the benefits of human challenge